Radiotherapy in combination with vascular-targeted therapies

Area of Science:

• Oncology
• Vascular Biology
• Radiation Oncology

Background:

• Tumor vasculature is crucial for cancer growth, leading to the development of vascular-targeted therapies.
• Antiangiogenic agents (AAs) inhibit new blood vessel formation, while vascular-disrupting agents (VDAs) target existing tumor vessels.
• Combining these agents with conventional therapies, like radiotherapy, is a promising strategy.

Purpose of the Study:

• To explore the rationale and potential of combining vascular-targeted therapies with radiation for cancer treatment.
• To review preclinical and early clinical evidence supporting this combined approach.

Main Methods:

• Review of existing literature on antiangiogenic agents, vascular-disrupting agents, and radiotherapy.
• Analysis of preclinical studies demonstrating the effects of vascular-targeted therapies on the tumor microenvironment.
• Evaluation of early-phase clinical trials investigating combined treatment strategies.

Main Results:

• Vascular-targeted therapies (AAs and VDAs) can modify the tumor microenvironment to improve radiation response.
• Preclinical and early clinical studies indicate therapeutic potential for combined vascular-targeted therapy and radiation.
• Concerns regarding potential increases in normal tissue toxicity have been identified.

Conclusions:

• There is a strong biological basis for combining vascular-targeted therapies with radiation.
• This combination strategy has demonstrated therapeutic potential in preclinical and early clinical settings.
• Further investigation is warranted to optimize treatment and manage potential toxicities.